Results 41 to 50 of about 457 (170)
Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review
Journal of Orthopaedic Research, Volume 41, Issue 8, Page 1781-1791, August 2023., 2023 Abstract Acute low back pain (LBP) imposes a significant socioeconomical burden as it is the condition that, worldwide, cause the most disability. Nonetheless, the literature regarding the best pharmacological management of acute LBP is limited, and the indications available in the literature are conflicting.
Alice Baroncini +5 more
wiley +1 more source
Analgesic Medication in Fibromyalgia Patients: A Cross‐Sectional Study
Pain Research and Management, Volume 2022, Issue 1, 2022., 2022 There is no approved drug for fibromyalgia syndrome (FMS) in Europe. In the German S3 guideline, amitriptyline, duloxetine, and pregabalin are recommended for temporary use. The aim of this study was to cross‐sectionally investigate the current practice of medication in FMS patients in Germany. We systematically interviewed 156 patients with FMS, while
H.-C. Aster +5 more
wiley +1 more source
Emerging Potential Therapeutic Targets of Ferroptosis in Skeletal Diseases
Oxidative Medicine and Cellular Longevity, Volume 2022, Issue 1, 2022., 2022 Ferroptosis is a new programmed cell death characterized by the accumulation of lipid peroxidation mediated by iron and inflammation. Since the transcentury realization of ferroptosis as an iron‐dependent modality of nonapoptotic cell death in 2012, there has been growing interest in the function of ferroptosis and its relationship to clinical diseases.
Xin Liu +8 more
wiley +1 more source
Retraction notice to “The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury” [Saudi Pharm. J. 25 (2017) 655–659] [PDF]
Saudi Pharmaceutical Journal, 2020 Dejun Luo +7 more
doaj +2 more sources
Неврология, нейропсихиатрия, психосоматика, 2023 Non-specific low back pain (LBP) occurs in most people at least once in a lifetime. In city polyclinics, every fourth patient complains of LBP. During the COVID-19 pandemic, the prevalence of acute non-specific LBP and chronic LBP have increased due to ...
V. A. Golovacheva +2 more
doaj +1 more source
Results of the post-registration clinical study “PARUS” on efficiency and safety assessment of Mydocalm-Richter for local injection therapy of a myofascial trigger zone [PDF]
Терапевтический архив, 2018 Aim. The “PARUS” program included investigation of the analgesic, muscle relaxant and sedative effects of Mydocalm-Richter which acts as central muscle relaxant in patients with myofascial pain syndrome, taking into account its registered indication for ...
F I Devlikamova
doaj +1 more source
Diagnosis and treatment of chronic pelvic pain syndrome
Неврология, нейропсихиатрия, психосоматика, 2022 The management of patients with chronic pelvic pain (CPP) is a serious problem, the solution of which is in the complex interdisciplinary approach. The article describes the neurological aspects of the disease, including musculoskeletal and neurogenic ...
L. T. Akhmedzhanova +3 more
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2018 Tolperisone HCl is a centrally muscles relaxant drug. It is a highly water-soluble drug. It has a biological half-life of 1.5–2.5 h. It has absorption window in the small intestine and unstable in intestinal pH 4 to 7.
Ankita U. Patel +3 more
doaj +1 more source
Неврология, нейропсихиатрия, психосоматика, 2019 The concurrent use of muscle relaxants and nonsteroidal anti-inflammatory drugs (NSAIDs) is a promising treatment for painful muscle hypertonia and convulsive states.Objective: to identify the most effective and safe synergist combinations of tolperisone
I. Yu. Torshin +4 more
doaj +1 more source
Muscular factor in the development of musculoskeletal pain. Treatment options
Неврология, нейропсихиатрия, психосоматика, 2022 The importance of the muscular factor, which is traditionally considered in myofascial pain syndrome (MFPS), in the development and maintenance of musculoskeletal pain (MSP) is actively discussed.
A. I. Isaikin, T. I. Nasonova
doaj +1 more source